Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy.

Dana-Farber Cancer Institute, Boston, MA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Boston, MA
Treatments:ChemotherapyHospital:Dana-Farber Cancer Institute
Drugs:Journal:Link
Date:Apr 2007

Description:

Patients: This phase II trial involved twenty-six patients with metastatic melanoma. There were 12 men and 14 women. The median age was 45 years, ranging from 28-70. The patients’ disease had progressed during or after they were treated with biochemotherapy: cisplatin, vinblastine, dacarbazine, interleukin-2 and interferon alfa-2b.

Treatment: Patients were treated with an infusion of high-dose bolus interleukin-2.

Toxicity: Grade 3 and 4 toxicities included anemia, leukopenia, thrombocytopenia, tachycardia, hypotension, nausea, vomiting, diarrhea, renal and hepatic abnormalities (oliguria and increased bilirubin), infection, rash, and fatique/delirium. Each of these occurred in less than 10 patients, except for hepatic (liver) abnormality, which occurred in 13 patients.

Results: The median overall survival was 9.6 months (41.9 weeks). The median progression-free survival was 10 weeks.

Correspondence: Dr. Sanjiv S. Agarwala




Back